The impact of micronized progesterone on breast cancer risk: a systematic review

References

• Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet Gynecol Surv 1978;33:69–81
   PubMedGoogle Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19:316–28
   PubMed Web of Science ®Google Scholar
• Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol 2017;33:87–92
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
   PubMed Web of Science ®Google Scholar
• So¨Derqvist G, Murkes D, Lalitkumar P. Percutaneous estradiol/oral micronized progesterone gives considerably less mammary tumor increasing gene expressions than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo: results from micro-array and PCR data from core needle biopsies. Climacteric 2016;19:34
   Google Scholar
• Asi N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev 2016;5:121
   PubMedGoogle Scholar
• Espie M, Daures JP, Chevallier T, Mares P, Micheletti MC, De Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol 2007;23:391–7
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262–9
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30–7
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Karlamangla A, Huang MH, Ursin G, Guan M, Greendale GA. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. Arch Intern Med 2006;166:1578–84
   PubMed Web of Science ®Google Scholar
• Lee E, Ingles SA, Van Den Berg D, et al. Progestogen levels, progesterone receptor gene polymorphisms, and mammographic density changes: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Menopause 2012;19:302–10
   PubMed Web of Science ®Google Scholar
• Pettersen PC, Raundahl J, Loog M, Nielsen M, Tanko LB, Christiansen C. Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms. Climacteric 2008;11:135–43
   PubMed Web of Science ®Google Scholar
• Murkes D, Lalitkumar PG, Leifland K, Lundstrom E, Soderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol 2012;28:12–15
   PubMed Web of Science ®Google Scholar
• Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188–91
   PubMed Web of Science ®Google Scholar
• Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91
   PubMed Web of Science ®Google Scholar
• Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9
   PubMed Web of Science ®Google Scholar
• de Lignieres B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002;5:332–40
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138–43
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014;145:535–43
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women. A randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 2013;8:e78016
   PubMed Web of Science ®Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010;172:1394–403
   PubMed Web of Science ®Google Scholar
• The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• Armeni E, Lambrinoudaki I, Ceausu I, et al. Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS). Maturitas 2016;89:63–72
   PubMed Web of Science ®Google Scholar
• Sarri G, Davies M, Lumsden MA. Guideline Development Group. Diagnosis and management of menopause: summary of NICE guidance. BMJ 2015;351:h5746
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy: identifying. Use trends and knowledge gaps among US women. Menopause 2015;22:926–36
   PubMed Web of Science ®Google Scholar
• Pinkerton JV. Think twice before prescribing custom-compounded bioidentical hormone therapy. J Womens Health (Larchmt) 2014;23:631–3
   PubMed Web of Science ®Google Scholar
• Pinkerton JV. What are the concerns about custom-compounded ‘bioidentical’ hormone therapy? Menopause 2014;21:1298–300
   PubMed Web of Science ®Google Scholar
• Sickles E, D'Orsi CJ, Bassett LW, et al. ACR BI-RADS mammography. In D’Orsi CJ, Sickles EA, Mendelson E, et al., eds. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013
   Google Scholar
• Byng JW, Yaffe MJ, Jong RA, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 1998;18:1587–98
   PubMed Web of Science ®Google Scholar
• Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol 1994;39:1629–38
   PubMed Web of Science ®Google Scholar
• Yaffe MJ. Mammographic density. Measurement of mammographic density. Breast Cancer Res 2008;10:209
   PubMed Web of Science ®Google Scholar
• Vachon CM, van Gils CH, Sellers TA, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 2007;9:217
   PubMed Web of Science ®Google Scholar
• Gierach GL, Ichikawa L, Kerlikowske K, et al. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 2012;104:1218–27
   PubMedGoogle Scholar
• van Duijnhoven FJ, Peeters PH, Warren RM, et al. Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 2007;25:1323–28
   PubMed Web of Science ®Google Scholar
• Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA. Accuracy of assigned BI-RADS breast density category definitions. Acad Radiol 2006;13:1143–9
   PubMed Web of Science ®Google Scholar
• Kerlikowske K, Grady D, Barclay J, et al. Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System. J Natl Cancer Inst 1998;90:1801–9
   PubMedGoogle Scholar
• Ciatto S, Houssami N, Apruzzese A, et al. Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. Breast 2005;14:269–75
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Systemic progesterone therapy–Oral, vaginal, injections and even transdermal? Maturitas 2014;79:248–55
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125–34
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Cline JM. Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat 2009;114:233–42
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar